Huang and colleagues found that ccRCC tumors can be re-sensitized to sunitinib treatment with the coadministration of an IL-8 neutralizing antibody and confirmed that IL-8 is a potent contributor to sunitinib resistance in ccRCC (Huang et al., 2010). Here, CXCL8 is linked to nonpapillary renal cell carcinoma.